MovDisordV3, Main, Exploration, bibRecord, 003242

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Identifieur interne : 003242 ( Main/Exploration ); précédent : 003241; suivant : 003243

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Auteurs : Kenichi Sato [Japon] ; Taku Hatano [Japon] ; Kazuo Yamashiro [Japon] ; Maki Kagohashi [Japon] ; Kenya Nishioka [Japon] ; Nana Izawa [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Hideo Mori [Japon] ; Yoshikuni Mizuno [Japon]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-09.

RBID : ISTEX:EB675D4AB48DF3E3F64195AC1729FF8111D21E8A

Descripteurs français

Pascal (Inist)
- AMP, Fluctuation, Mortalité, Parkinson maladie, Pronostic, Système nerveux pathologie, Traitement.
Wicri :
- geographic : Japon.
- topic : Mortalité.

English descriptors

KwdEn :
- AMP, Adult, Age Factors, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Cohort Studies, Disability Evaluation, Drug Therapy, Combination, Dyskinesia, Drug-Induced (classification), Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (epidemiology), Female, Fluctuations, Hoehn & Yahr stage, Humans, Japan, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Middle Aged, Mobility Limitation, Mortality, Nervous system diseases, Neurologic Examination, Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Prognosis, Retrospective Studies, Severity of Illness Index, Sex Factors, Treatment, mortality, prognosis, treatment.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- geographic : Japan.
- classification : Dyskinesia, Drug-Induced, Parkinson Disease.
- diagnosis : Dyskinesia, Drug-Induced, Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Dyskinesia, Drug-Induced, Parkinson Disease.
- Adult, Age Factors, Aged, Cohort Studies, Disability Evaluation, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Mobility Limitation, Neurologic Examination, Prognosis, Retrospective Studies, Severity of Illness Index, Sex Factors.

Abstract

We report a long‐term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long‐term outcome was evaluated in this subcohort of the patients. We examined the duration to reach Stage III, IV, and V, and the duration to develop wearing off and dyskinesia. Time to reach Stage III was slightly but significantly shorter in women, in that 23.8% of men and 35.3% of women reached Stage III by the end of the 5th year; 49.7% of men and 63.3% of women reached Stage III by the end of the 10th year, and 88.9% of men and 79.9% of women by the end of the 15th year (P < 0.001). Also, durations to develop wearing off and dyskinesia were shorter in women compared to men. These data suggest that the disease progression may be slightly faster for women. Young‐onset patients showed significantly longer duration to reach Stage III, IV, and V but shorter duration to develop wearing off and dyskinesia. Not many studies are available in the literature on the long‐term outcome of PD, and our data would be useful as a reference. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/EB675D4AB48DF3E3F64195AC1729FF8111D21E8A/fulltext/pdf

DOI: 10.1002/mds.20993

Affiliations:

Japon

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations</title>
<author><name sortKey="Sato, Kenichi" sort="Sato, Kenichi" uniqKey="Sato K" first="Kenichi" last="Sato">Kenichi Sato</name>
</author>
<author><name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
</author>
<author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
</author>
<author><name sortKey="Kagohashi, Maki" sort="Kagohashi, Maki" uniqKey="Kagohashi M" first="Maki" last="Kagohashi">Maki Kagohashi</name>
</author>
<author><name sortKey="Nishioka, Kenya" sort="Nishioka, Kenya" uniqKey="Nishioka K" first="Kenya" last="Nishioka">Kenya Nishioka</name>
</author>
<author><name sortKey="Izawa, Nana" sort="Izawa, Nana" uniqKey="Izawa N" first="Nana" last="Izawa">Nana Izawa</name>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
</author>
<author><name sortKey="Mori, Hideo" sort="Mori, Hideo" uniqKey="Mori H" first="Hideo" last="Mori">Hideo Mori</name>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:EB675D4AB48DF3E3F64195AC1729FF8111D21E8A</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20993</idno>
<idno type="url">https://api.istex.fr/document/EB675D4AB48DF3E3F64195AC1729FF8111D21E8A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000218</idno>
<idno type="wicri:Area/Istex/Curation">000218</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D01</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Sato K:prognosis:of:parkinson</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16763980</idno>
<idno type="wicri:Area/PubMed/Corpus">002C03</idno>
<idno type="wicri:Area/PubMed/Curation">002C03</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B42</idno>
<idno type="wicri:Area/Ncbi/Merge">001733</idno>
<idno type="wicri:Area/Ncbi/Curation">001733</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001733</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Sato K:prognosis:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">004555</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0518092</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A04</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001317</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001944</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Sato K:prognosis:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">004A39</idno>
<idno type="wicri:Area/Main/Curation">003242</idno>
<idno type="wicri:Area/Main/Exploration">003242</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations</title>
<author><name sortKey="Sato, Kenichi" sort="Sato, Kenichi" uniqKey="Sato K" first="Kenichi" last="Sato">Kenichi Sato</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kagohashi, Maki" sort="Kagohashi, Maki" uniqKey="Kagohashi M" first="Maki" last="Kagohashi">Maki Kagohashi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nishioka, Kenya" sort="Nishioka, Kenya" uniqKey="Nishioka K" first="Kenya" last="Nishioka">Kenya Nishioka</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Izawa, Nana" sort="Izawa, Nana" uniqKey="Izawa N" first="Nana" last="Izawa">Nana Izawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mori, Hideo" sort="Mori, Hideo" uniqKey="Mori H" first="Hideo" last="Mori">Hideo Mori</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo. Tokyo</wicri:regionArea>
<wicri:noRegion>Bunkyo. Tokyo</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1384">1384</biblScope>
<biblScope unit="page" to="1395">1395</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">EB675D4AB48DF3E3F64195AC1729FF8111D21E8A</idno>
<idno type="DOI">10.1002/mds.20993</idno>
<idno type="ArticleID">MDS20993</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMP</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Cohort Studies</term>
<term>Disability Evaluation</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (classification)</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Dyskinesia, Drug-Induced (epidemiology)</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Hoehn & Yahr stage</term>
<term>Humans</term>
<term>Japan</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mobility Limitation</term>
<term>Mortality</term>
<term>Nervous system diseases</term>
<term>Neurologic Examination</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prognosis</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Sex Factors</term>
<term>Treatment</term>
<term>mortality</term>
<term>prognosis</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Disability Evaluation</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mobility Limitation</term>
<term>Neurologic Examination</term>
<term>Prognosis</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Sex Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>AMP</term>
<term>Fluctuation</term>
<term>Mortalité</term>
<term>Parkinson maladie</term>
<term>Pronostic</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Mortalité</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report a long‐term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long‐term outcome was evaluated in this subcohort of the patients. We examined the duration to reach Stage III, IV, and V, and the duration to develop wearing off and dyskinesia. Time to reach Stage III was slightly but significantly shorter in women, in that 23.8% of men and 35.3% of women reached Stage III by the end of the 5th year; 49.7% of men and 63.3% of women reached Stage III by the end of the 10th year, and 88.9% of men and 79.9% of women by the end of the 15th year (P < 0.001). Also, durations to develop wearing off and dyskinesia were shorter in women compared to men. These data suggest that the disease progression may be slightly faster for women. Young‐onset patients showed significantly longer duration to reach Stage III, IV, and V but shorter duration to develop wearing off and dyskinesia. Not many studies are available in the literature on the long‐term outcome of PD, and our data would be useful as a reference. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Sato, Kenichi" sort="Sato, Kenichi" uniqKey="Sato K" first="Kenichi" last="Sato">Kenichi Sato</name>
</noRegion>
<name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<name sortKey="Izawa, Nana" sort="Izawa, Nana" uniqKey="Izawa N" first="Nana" last="Izawa">Nana Izawa</name>
<name sortKey="Kagohashi, Maki" sort="Kagohashi, Maki" uniqKey="Kagohashi M" first="Maki" last="Kagohashi">Maki Kagohashi</name>
<name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<name sortKey="Mori, Hideo" sort="Mori, Hideo" uniqKey="Mori H" first="Hideo" last="Mori">Hideo Mori</name>
<name sortKey="Nishioka, Kenya" sort="Nishioka, Kenya" uniqKey="Nishioka K" first="Kenya" last="Nishioka">Kenya Nishioka</name>
<name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003242 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003242 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:EB675D4AB48DF3E3F64195AC1729FF8111D21E8A
   |texte=   Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.